Clinical Trials
The Newro Foundation - the only private brain tumour foundation actively doing research in Australia. We conduct a number of clinical trials in collaboration with partners throughout Australia and the world. Read on to find our more about our latest research.
Investigator initiated Neo-Adjuvant therapy for High Grade Gliomas
A Pilot Study of the use of Metformin, Atorvastatin and Celecoxib from presurgery to 9 months post diagnosis in patients with Malignant Glioma: A Phase 1 Study
These commonly used medications Metformin, Atorvastatin and Celecoxib have shown in preclinical trials to have metabolic effects on brain cancer cells, cytotoxic effects on glioma stem cell growth and properties enhancing the effects of chemotherapy and radiotherapy. In the study we want to show that the use of neo-adjuvant Metformin, Atorvastatin and Celecoxib is safe when commenced prior to initial surgery, and continued for a total of 9 months throughout postoperative chemoradiation and adjuvant chemotherapy.
Clinical Trial Status - completed
A Phase II trial evaluating exercise for patients with brain cancer (BRACE Study)
This clinical trial aims to determine the feasibility and safety of a structured exercise program in patients with primary brain cancer. It is hoped that a tailored exercise program will have a positive affect on Quality of Life (general and cancer-specific), fatigue, physical function, anxiety and depression, and leisure time. This study is a collaboration between Queensland University of Technology (QUT), the ICON Cancer Foundation, Aspire Fitness and Rehabilitation and the Newro Foundation.
Clinical Trial Status - completed
Adjuvant Immunotherapy for Primary Glioblastoma
Vaccine Development T Cell Vaccination
The Newro Foundation in collaboration with QIMR are conducting a longitudinal cross sectional study with people with brain tumours investigating the development of a vaccine to prevent Human Cytomegalovirus (HCMV) disease. Through this study, research hope to gain a better understanding of how the immune system responds to HCMV and how cytoxic T cells recognise HCMV cells.
Clinical Trial Status - completed
Phase I* clinical trial to assess the safety and tolerability of autologous CMV-specific T cells as adjuvant therapy for primary Glioblastoma Multiforme
This clinical trial investigated the association between Human Cytomegalovirus (HCMV) and Glioblastoma Multiforme (GBM) in patients with newly diagnosed with primary brain tumours. The research focused on the safety and effectiveness of HCMV-specific T cells and evaluated their impact on progression-free survival.
*Phase I - a clinical trial that has never been undertaken in humans
Clinical Trial Status - completed
Killer T Cell Therapy for Gliobastoma
This clinical trial investigated the association between Human Cytomegalovirus (HCMV) and Glioblastoma Multiforme (GBM) in patients with primary brain tumours where their cancer has recurred. The research focused on the safety and effectiveness of HCMV-specific T cells and evaluate their impact on progression-free survival.
Clinical Trial Status - completed
Despite these clinical trials being completed, the Newro Foundation continues to monitor the ongoing effect of autologous CMV-specific T cells in their clinical trial volunteers.
Improving Surgical Intervention for Brain Tumours
Phase I dose escalation/expansion study of BLZ-100 administered by intravenous infection in adult subjects with glioma undergoing surgery.
BLZ-100 is an experimental product that is thought to bind with cancer cells and forms a tumour paint. BLZ-100 was given to patients 2-24 hours prior to surgery. It contains a modified dye that fluoresces under a specific light source so that the surgeon can see the cancer cells using special imaging machines during surgery. This study focused on patients with primary brain tumours undergoing surgical interventions. collaborative initiative between BLAZE Bioscience (USA), Cedars Sinai Medical Centre (USA) and the Newro Foundation.
Clinical Trial Status - completed
